Gemeinsamer Bundesausschuss

Resolution

of the Federal Joint Committee (G-BA) on the Suspension of the Consultation Procedure under Section 35a paragraph 3b SGB V: Marstacimab (haemophilia A and B); requirement of routine practice data collection and evaluations

of 5 December 2024

The Federal Joint Committee (G-BA) decided the following at its session on 5 December 2024:

I. The consultation procedure on the requirement of routine practice data collection and evaluations according to Section 35a paragraph 3b SGB V for the active ingredient marstacimab in the treatment of

"Adults and adolescents aged 12 years and older with severe haemophilia A without factor VIII inhibitors or with moderate-to-severe haemophilia B without factor IX inhibitors"

is suspended.

II. The resolution will enter into force on the day of its publication on the website of the G-BA on 5 December 2024.

The justification to this resolution will be published on the website of the G-BA at www.g-ba.de.

Berlin, 5 December 2024

Federal Joint Committee (G-BA)
in accordance with Section 91 SGB V
The Chair

Prof. Hecken